Amylyx to answer for single-study ALS application at FDA advisory panel

The single clinical trial Amylyx Pharmaceuticals presented to support approval of its ALS drug is “not exceptionally persuasive,” according to the briefing document the FDA released ahead of this week's planned advisory panel, which will review the treatment.